LONDON--Pharmaceutical company Vectura Group PLC (VEC.LN) said Thursday that it will receive milestone payments totaling $20 million from Novartis (NOVN.VX), following the decision by U.S. Food and Drug Administration to accept two new drug applications made by Novartis.

The regulatory has accepted Novartis' new drug applications for QVA149 and NVA237 for the long-term maintenance treatment of chronic obstructive pulmonary disease. The acceptances have triggered milestone payments to Vectura of $12.5 million and $7.5 million, respectively.

Shares of Vectura at 1119 GMT trading 1.2%, at 151 pence.

Write to Tapan Panchal at tapan.panchal@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novartis Charts.